Gene · 2217
Papers4,523
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
281 to 300 of 4,523
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Open-label study of efgartigimod in seronegative myasthenia gravis. | Ther Adv Neurol Disord | 2025 | 41180124 | PubTator, text mining | PubMed |
| Fc-Engineered B7-H3 Antibody with Prolonged Serum Half-Life for Enhanced Cancer Therapy. | Mol Pharm | 2025 | 41168933 | PubTator, text mining | PubMed |
| Identification of an effective treatment for liver fibrosis based on a long acting easy to deliver TNF-α-derived peptide. | Pharmacol Res | 2025 | 41161461 | PubTator, text mining | PubMed |
| Case Report: Efgartigimod demonstrates significant clinical efficacy in double seropositive myasthenia gravis: a case report of a rare variant and analysis of pathomechanisms. | Front Immunol | 2025 | 41159035 | PubTator, text mining | PubMed |
| Management of Myasthenic Crisis and Emerging Roles of Molecularly Targeted Therapies: A Narrative Review. | Neurol Int | 2025 | 41149784 | PubTator, text mining | PubMed |
| Integrated proteomic and metabolomic analysis elucidates the effects and mechanisms of Qiziyusi decoction on IVF outcomes in advanced maternal age infertility. | Front Endocrinol (Lausanne) | 2025 | 41141348 | PubTator, text mining | PubMed |
| Safety profile of complement C5 inhibitors and FcRn inhibitors in the treatment of myasthenia gravis: analysis of the FAERS database and disease-gene interaction network. | Front Immunol | 2025 | 41132654 | PubTator, text mining | PubMed |
| Immunoglobulin G Fc engineering for localized therapy: Eliminating neonatal Fc receptor interactions and ensuring purification using protein A. | Protein Sci | 2025 | 41123423 | PubTator, text mining | PubMed |
| From promise to practice: evaluating the clinical impact of FcRn inhibition in IgG-mediated autoimmune rheumatic diseases. | Front Immunol | 2025 | 41112287 | PubTator, text mining | PubMed |
| Modular generation of multispecific antibodies using protein trans-splicing. | MAbs | 2025 | 41104655 | PubTator, text mining | PubMed |
| Future perspectives on myasthenia gravis and related disorders. | Int Rev Neurobiol | 2025 | 41101822 | PubTator, text mining | PubMed |
| Novel treatments for myasthenia gravis. | Int Rev Neurobiol | 2025 | 41101819 | PubTator, text mining | PubMed |
| "Baby You're Just Not Right for Me": The Various Problems of Feto-Maternal Incompatibilities. | Transfus Med Hemother | 2025 | 41089466 | PubTator, text mining | PubMed |
| Dynamic Changes in Peripheral Immune Cells During Efgartigimod Treatment in Naive Generalized Myasthenia Gravis. | CNS Neurosci Ther | 2025 | 41084336 | PubTator, text mining | PubMed |
| Two paths for turning the tide: complement and FcRn inhibition to overcome refractory myasthenia gravis. | Neurol Sci | 2025 | 41053529 | PubTator, text mining | PubMed |
| Antibody Engineering for Receptor-Mediated Transcytosis Across the Blood-Brain Barrier. | Bioconjug Chem | 2025 | 41031862 | PubTator, text mining | PubMed |
| Efgartigimod for treating Guillain-Barré syndrome with poor response to intravenous immunoglobulin: a case report. | BMC Neurol | 2025 | 41029230 | PubTator, text mining | PubMed |
| Tailored collagen binding of albumin-fused hyperactive coagulation factor IX dictates in vivo distribution and functional properties. | Nat Commun | 2025 | 41022699 | PubTator, text mining | PubMed |
| An evaluation of nipocalimab for the treatment of generalized myasthenia gravis. | Expert Opin Biol Ther | 2025 | 41021216 | PubTator, text mining | PubMed |
| "Single molecule tracking unveils distinct FcγRIIB and FcRn plasma membrane dynamics". | Arch Biochem Biophys | 2025 | 41016418 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2217/papers?page=15